121 related articles for article (PubMed ID: 22647518)
21. Synthesis of 3-(Pyridin-2-yl)quinazolin-2,4(1
Baykova SO; Geyl KK; Baykov SV; Boyarskiy VP
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108796
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes.
Storey RF; Gurbel PA; Ten Berg J; Bernaud C; Dangas GD; Frenoux JM; Gorog DA; Hmissi A; Kunadian V; James SK; Tanguay JF; Tran H; Trenk D; Ufer M; Van der Harst P; Van't Hof AWJ; Angiolillo DJ
Eur Heart J; 2020 Sep; 41(33):3132-3140. PubMed ID: 31994703
[TBL] [Abstract][Full Text] [Related]
23. Involvement of P2 receptors in hematopoiesis and hematopoietic disorders, and as pharmacological targets.
Filippin KJ; de Souza KFS; de Araujo Júnior RT; Torquato HFV; Dias DA; Parisotto EB; Ferreira AT; Paredes-Gamero EJ
Purinergic Signal; 2020 Mar; 16(1):1-15. PubMed ID: 31863258
[TBL] [Abstract][Full Text] [Related]
24. Current Antithrombotic Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Interventions.
Pesarini G; Ariotti S; Ribichini F
Interv Cardiol; 2014 Apr; 9(2):94-101. PubMed ID: 29588785
[TBL] [Abstract][Full Text] [Related]
25. Effects of P2Y12 receptor antagonists beyond platelet inhibition--comparison of ticagrelor with thienopyridines.
Nylander S; Schulz R
Br J Pharmacol; 2016 Apr; 173(7):1163-78. PubMed ID: 26758983
[TBL] [Abstract][Full Text] [Related]
26. Switching P2Y12-receptor inhibitors in patients with coronary artery disease.
Rollini F; Franchi F; Angiolillo DJ
Nat Rev Cardiol; 2016 Jan; 13(1):11-27. PubMed ID: 26283269
[TBL] [Abstract][Full Text] [Related]
27. Effect of Shenzhu Guanxin Recipe () on patients with angina pectoris after percutaneous coronary intervention: A prospective, randomized controlled trial.
Xu DP; Wu HL; Lan TH; Wang X; Sheng XG; Lin Y; Li S; Zheng CY
Chin J Integr Med; 2015 Jun; 21(6):408-16. PubMed ID: 26063318
[TBL] [Abstract][Full Text] [Related]
28. Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials.
Angiolillo DJ; Bhatt DL; Steg PG; Stone GW; White HD; Gibson CM; Hamm CW; Price MJ; Prats J; Liu T; Mahaffey KW; Harrington RA
J Thromb Thrombolysis; 2015 Oct; 40(3):317-22. PubMed ID: 26024789
[TBL] [Abstract][Full Text] [Related]
29. Novel antiplatelet agents in cardiovascular medicine.
Rafeedheen R; Bliden KP; Liu F; Tantry US; Gurbel PA
Curr Treat Options Cardiovasc Med; 2015 Jun; 17(6):383. PubMed ID: 25895737
[TBL] [Abstract][Full Text] [Related]
30. Use of novel antiplatelet agents in acute coronary syndromes.
Luna M; Holper EM
Curr Atheroscler Rep; 2015 Mar; 17(3):483. PubMed ID: 25663559
[TBL] [Abstract][Full Text] [Related]
31. Comparison of new adenosine diphosphate receptor antagonists with clopidogrel in patients with coronary artery disease: a meta-analysis.
Bae JS; Jang JS
Heart Vessels; 2016 Mar; 31(3):275-87. PubMed ID: 25374111
[TBL] [Abstract][Full Text] [Related]
32. Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments.
Thind GS; Parida R; Gupta N
Ther Clin Risk Manag; 2014; 10():885-900. PubMed ID: 25364258
[TBL] [Abstract][Full Text] [Related]
33. Novel antiplatelet agents in acute coronary syndrome.
Franchi F; Angiolillo DJ
Nat Rev Cardiol; 2015 Jan; 12(1):30-47. PubMed ID: 25286881
[TBL] [Abstract][Full Text] [Related]
34. Significance of antiplatelet therapy in emergency myocardial infarction treatment.
Komosa A; Lesiak M; Siniawski A; Mularek-Kubzdela T; Grajek S
Postepy Kardiol Interwencyjnej; 2014; 10(1):32-9. PubMed ID: 24799926
[TBL] [Abstract][Full Text] [Related]
35. Platelet function profiles in patients with diabetes mellitus.
Rollini F; Franchi F; Muñiz-Lozano A; Angiolillo DJ
J Cardiovasc Transl Res; 2013 Jun; 6(3):329-45. PubMed ID: 23404189
[TBL] [Abstract][Full Text] [Related]
36. Biomarkers in acute coronary artery disease.
Freynhofer MK; Tajsić M; Wojta J; Huber K
Wien Med Wochenschr; 2012 Nov; 162(21-22):489-98. PubMed ID: 23143510
[TBL] [Abstract][Full Text] [Related]
37. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.
Welsh RC; Rao SV; Zeymer U; Thompson VP; Huber K; Kochman J; McClure MW; Gretler DD; Bhatt DL; Gibson CM; Angiolillo DJ; Gurbel PA; Berdan LG; Paynter G; Leonardi S; Madan M; French WJ; Harrington RA;
Circ Cardiovasc Interv; 2012 Jun; 5(3):336-46. PubMed ID: 22647518
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial.
Angiolillo DJ; Welsh RC; Trenk D; Neumann FJ; Conley PB; McClure MW; Stephens G; Kochman J; Jennings LK; Gurbel PA; Wójcik J; Dabrowski M; Saucedo JF; Stumpf J; Buerke M; Broderick S; Harrington RA; Rao SV
Circ Cardiovasc Interv; 2012 Jun; 5(3):347-56. PubMed ID: 22619259
[TBL] [Abstract][Full Text] [Related]
39. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI).
Leonardi S; Rao SV; Harrington RA; Bhatt DL; Gibson CM; Roe MT; Kochman J; Huber K; Zeymer U; Madan M; Gretler DD; McClure MW; Paynter GE; Thompson V; Welsh RC
Am Heart J; 2010 Jul; 160(1):65-72. PubMed ID: 20598974
[TBL] [Abstract][Full Text] [Related]
40. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial.
Berger JS; Roe MT; Gibson CM; Kilaru R; Green CL; Melton L; Blankenship JD; Metzger DC; Granger CB; Gretler DD; Grines CL; Huber K; Zeymer U; Buszman P; Harrington RA; Armstrong PW
Am Heart J; 2009 Dec; 158(6):998-1004.e1. PubMed ID: 19958867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
